This award, funded by the ALS Association and American Brain Foundation in collaboration with AAN, aims to encourage early career investigators in ALS clinical studies by providing $75,000 per year for three years, plus a $5,000 per year stipend to support education and research-related costs. Applicants must be AAN members interested in an academic career in neurological research and have completed residency or a Ph.D. no more than seven years prior to the beginning of this award (July 1, 2026). All applications must be received by September 9, 2025.
In addition, the Foundation for the National Institutes of Health, on behalf of the Accelerating Medicines Partnership® in ALS (AMP® ALS), has launched a request for information (RFI) regarding current gaps and emerging opportunities in biomarker research for ALS. This RFI is actively seeking ideas, innovative information, and valuable insights to help identify the most promising opportunities for biomarker research in ALS, including the ALS-frontotemporal dementia (FTD) clinical spectrum, as well as recommendations for the collection of clinical biospecimens to facilitate such research. The full RFI can be accessed here. Responses are due December 31, 2025, 5 p.m. ET.
Richard Olney Clinician Scientist Development Award in ALS